Arcus Biosciences, Inc.
Clinical trials sponsored by Arcus Biosciences, Inc., explained in plain language.
-
New combo therapy aims to stall advanced kidney cancer
Disease control Recruiting nowThis study tests whether adding the experimental drug casdatifan to the standard drug cabozantinib helps people with advanced clear cell kidney cancer live longer without their disease getting worse. About 720 adults whose cancer progressed after prior immunotherapy will receive …
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
New drug combo trial aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new drug called casdatifan (AB521) in people with advanced kidney cancer or other solid tumors that haven't responded to standard treatments. The goal is to find safe doses and see how well the drug works alone or combined with other cancer therapie…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC